Valuation of different treatment courses of recombinant human brain natriuretic peptide in heart failure patients over 70 years old

A single-center, prospective, cohort study on the efficacy and anti-myocardial fibrosis mechanism of recombinant human brain natriuretic peptide (rBNP) in the treatment of patients aged 70 years and above with heart failure (HF) for both 7 days and beyond 7 days' course

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2600116729

Enrollment

Unknown

Registered

2026-01-14

Start date

2026-01-20

Completion date

Unknown

Last updated

2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart failure

Interventions

Observation group:N/A

Eligibility

Sex/Gender

All

Age

70 Years to No maximum

Inclusion criteria

Inclusion criteria: Age >=70 years, meeting the standards of the 'Chinese Guidelines for the Diagnosis and Treatment of Heart Failure'; NYHA class II-IV heart failure, NT-proBNP >450 pg/mL, systolic blood pressure >=90 mmHg, signed informed consent.

Exclusion criteria

Exclusion criteria: 1.malignant tumor; 2.Patients with pathological changes in vital organs such as lungs, kidneys, or liver"; 3.allergic history to rhBNP; 4.dementia with psychiatric symptoms or violent tendencies;

Design outcomes

Primary

Measure	Time frame
NT-proBNP;	—

Countries

China

Contacts

Public ContactChen Yuan

Shanxi Bethune Hospital

chenyuan55@126.com+86 351 837 9146

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026